By Olivia Bugault

Sanofi SA said Thursday that the European Commission has granted a marketing authorization for Supemtek, a recombinant vaccine for the prevention of influenza in adults aged 18 or more.

"The authorization is based on clinical data demonstrating safety, immunogenicity and efficacy of Supemtek in two Phase-3 randomized controlled trials," the pharmaceutical giant said.

The first European launches should happen for the 2022-2023 influenza season, but there will be a possibility to have doses available in the 2021/2022 season in some countries, Sanofi said.

Write to Olivia Bugault at olivia.bugault@wsj.com

(END) Dow Jones Newswires

November 19, 2020 02:16 ET (07:16 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
過去 株価チャート
から 3 2024 まで 4 2024 Sanofiのチャートをもっと見るにはこちらをクリック
Sanofi (EU:SAN)
過去 株価チャート
から 4 2023 まで 4 2024 Sanofiのチャートをもっと見るにはこちらをクリック